Will cabozantinib be included in medical insurance in 2024?

As of 2024Cabozantinib has not yet been officially launched in China. Therefore, it cannot currently be included in domestic medical insurance reimbursement items. This situation is undoubtedly a reality that needs to be faced by many patients who are looking forward to reducing their financial burden through medical insurance.

As a multi-target anti-tumor drug, cabozantinib’s therapeutic effect has been widely recognized in a variety of solid tumors. It exists in two main forms: capsules (Cometriq) and tablets (Cabometyx). The capsule form is mainly used to treat medullary thyroid cancer, while the tablet form is targeted at the treatment of renal cell carcinoma, hepatocellular carcinoma and differentiated thyroid cancer. The formulas of these two dosage forms are different and therefore cannot be replaced with each other. Patients should make a decision based on the doctor's advice and their own condition when choosing.

Although cabozantinib has achieved remarkable results in foreign markets, the reason why it has not yet been launched in China may involve many considerations, including the drug approval process, market demand assessment, clinical trial results, etc. For domestic patients, this means that they are temporarily unable to purchase cabozantinib domestically through formal channels, nor can they enjoy the reimbursement policy of medical insurance.

Cabozantinib is not currently on the market in China. It is understood that the original research version and various generic versions of cabozantinib are already on the market in overseas markets. Among them, the price of the original research version of tablets is about 35,000 yuan, and the price of capsules is about 46,000 yuan. It is worth noting that the original research version of tablets produced in Türkiye performs well in terms of cost performance. In addition, the price of the generic version of cabozantinib available overseas is relatively affordable, ranging from RMB 800 to RMB 7,600, providing patients with more choices. If you have more questions about cabozantinib, please consult a regular overseas medical consulting company.

In general, cabozantinibhas not yet been launched in China and included in the medical insurance reimbursement items in 2024, which is a situation that requires attention for patients who are looking forward to using this drug. In the future, as the drug approval process advances and market demand changes, the domestic launch of cabozantinib may change. But before that, patients still need to make reasonable treatment choices based on their own condition and financial situation.